Literature DB >> 15213630

Tissue- and time-dependent upregulation of cytokine mRNA in a murine model for the multiple organ dysfunction syndrome.

Thomas J H Volman1, R Jan A Goris, Jos W M van der Meer, Thijs Hendriks.   

Abstract

OBJECTIVE: We sought to quantitate the course of specific cytokine mRNA expression in tissues that exhibit increasing histopathological changes in time in an animal model for the multiple organ dysfunction syndrome (MODS). SUMMARY BACKGROUND DATA: The development of treatment protocols for MODS requires elucidation of the mechanisms and mediators involved. To devise logical interventions, it is necessary to collect data on cytokine expression at tissue level during the development of MODS.
METHODS: Ninety-four C57BL/6 mice were given an intraperitoneal injection of 40 microg of lipopolysaccharide (LPS), followed by zymosan at a dose of 0.8 mg/g body weight 6 days later (day 0). Six additional animals did not receive zymosan and acted as controls. At several time points after zymosan injection, 6 randomly assigned, zymosan-treated animals were killed, and their livers, lungs, spleens, and kidneys were collected. mRNA expression of tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6, macrophage migration inhibiting factor, IL-12, interferon-gamma, and IL-10 was measured using a real-time reverse transcription-polymerase chain reaction assay.
RESULTS: The injection of zymosan induced an acute peritonitis, followed by an apparent recovery. From approximately day 6 onwards, animals started to display MODS-like symptoms. During the peritonitis phase, up-regulation of cytokine mRNA was limited. During the period of apparent recovery, cytokine mRNA expression strongly increased, mostly reaching its maximum at day 9 when deterioration of the clinical condition had already set in. The up-regulation of tumor necrosis factor-alpha mRNA was most pronounced, especially in the lungs and liver.
CONCLUSIONS: Interventions should preferentially be targeted against multiple cytokines and, at least in this model, there may be a treatment window well after the initial challenge.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15213630      PMCID: PMC1356386          DOI: 10.1097/01.sla.0000130725.52373.e7

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  36 in total

Review 1.  NF-kappaB activation and inhibition: a review.

Authors:  Zhengwu Sun; Roland Andersson
Journal:  Shock       Date:  2002-08       Impact factor: 3.454

Review 2.  Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome.

Authors:  J C Marshall
Journal:  Crit Care Med       Date:  2001-07       Impact factor: 7.598

3.  The role of tumor necrosis factor in the development of multiple organ failure in a murine model.

Authors:  D Burdon; T Tiedje; K Pfeffer; E Vollmer; P Zabel
Journal:  Crit Care Med       Date:  2000-06       Impact factor: 7.598

Review 4.  Multiple organ dysfunction syndrome: exploring the paradigm of complex nonlinear systems.

Authors:  A J Seely; N V Christou
Journal:  Crit Care Med       Date:  2000-07       Impact factor: 7.598

5.  Interleukin 10 mitigates the development of the zymosan-induced multiple organ dysfunction syndrome in mice.

Authors:  M J Jansen; T Hendriks; B M de Man; J W van der Meer; R J Goris
Journal:  Cytokine       Date:  1999-09       Impact factor: 3.861

Review 6.  IL-10 as a mediator in the HPA axis and brain.

Authors:  E M Smith; P Cadet; G B Stefano; M R Opp; T K Hughes
Journal:  J Neuroimmunol       Date:  1999-12       Impact factor: 3.478

7.  Beneficial effects of tempol, a membrane-permeable radical scavenger, on the multiple organ failure induced by zymosan in the rat.

Authors:  S Cuzzocrea; M C McDonald; E Mazzon; H M Filipe; T Centorrino; V Lepore; M L Terranova; A Ciccolo; A P Caputi; C Thiemermann
Journal:  Crit Care Med       Date:  2001-01       Impact factor: 7.598

8.  Organ damage in zymosan-induced multiple organ dysfunction syndrome in mice is not mediated by inducible nitric oxide synthase.

Authors:  Thomas J H Volman; R Jan A Goris; Michel van der Jagt; Fons A J van de Loo; Thijs Hendriks
Journal:  Crit Care Med       Date:  2002-07       Impact factor: 7.598

9.  Multiple organ failure in patients with cardiogenic shock is associated with high plasma levels of interleukin-6.

Authors:  Alexander Geppert; Angela Steiner; Gerlinde Zorn; Georg Delle-Karth; Maria Koreny; Markus Haumer; Peter Siostrzonek; Kurt Huber; Gottfried Heinz
Journal:  Crit Care Med       Date:  2002-09       Impact factor: 7.598

10.  Improved survival of TNF-deficient mice during the zymosan-induced multiple organ dysfunction syndrome.

Authors:  Thomas J H Volman; Thijs Hendriks; Albert A J Verhofstad; Bart-Jan Kullberg; R Jan A Goris
Journal:  Shock       Date:  2002-06       Impact factor: 3.454

View more
  7 in total

1.  Melanocortins protect against multiple organ dysfunction syndrome in mice.

Authors:  Alessandra Bitto; Francesca Polito; Domenica Altavilla; Natasha Irrera; Daniela Giuliani; Alessandra Ottani; Letteria Minutoli; Luca Spaccapelo; Maria Galantucci; Renzo Lodi; Giuseppe Guzzo; Salvatore Guarini; Francesco Squadrito
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

2.  Pentoxifylline does not improve outcome in a murine model for the multiple-organ dysfunction syndrome.

Authors:  T J H Volman; R J A Goris; T Hendriks
Journal:  Intensive Care Med       Date:  2005-02-15       Impact factor: 17.440

3.  Comparison of tissue-selective proinflammatory gene induction in mice infected with wild-type, DNA adenine methylase-deficient, and flagellin-deficient Salmonella enterica.

Authors:  Raphael Simon; Douglas M Heithoff; Michael J Mahan; Charles E Samuel
Journal:  Infect Immun       Date:  2007-09-24       Impact factor: 3.441

4.  Mesenteric lymph duct drainage attenuates acute lung injury in rats with severe intraperitoneal infection.

Authors:  Yanmin Zhang; Shukun Zhang; Naiqiang Tsui
Journal:  Inflammation       Date:  2015       Impact factor: 4.092

5.  Attenuation by l-thyroxine of oxidant-induced gut epithelial damage.

Authors:  Zahra Shahedi; Masoumeh Varedi; Zohreh Bagheri; Afagh Moatari; Hengameh Sharafpour
Journal:  Iran J Basic Med Sci       Date:  2019-09       Impact factor: 2.699

6.  Inhibition of zymosan-induced kidney dysfunction by tyrphostin AG-490.

Authors:  Petya Dimitrova; Valeriya Gyurkovska; Irina Shalova; Luciano Saso; Nina Ivanovska
Journal:  J Inflamm (Lond)       Date:  2009-05-05       Impact factor: 4.981

7.  Regulatory T cells are protective in systemic inflammation response syndrome induced by zymosan in mice.

Authors:  Wenyuan Jia; Li Cao; Shuangwen Yang; Hailong Dong; Yun Zhang; Haidong Wei; Wei Jing; Lichao Hou; Chen Wang
Journal:  PLoS One       Date:  2013-05-10       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.